Engineering the Genome
joint with Emerging Cellular Therapies: Cancer and Beyond
Organizer(s): Vic Myer and Erik Sontheimer Date: February 08 - 12, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
For important information on the coronavirus, please click here
Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement.
Scholarship Deadline: October 29 2019
Discounted Abstract Deadline: October 29 2019
Abstract Deadline: November 6 2019
Discounted Registration Deadline: December 10 2019
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email email@example.com if you are interested.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Sangamo Therapeutics, Inc.
Keystone Symposia thanks the following Donors for their support of $2,500 - $4,999.
We gratefully acknowledge the generous grant for this conference provided by:National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR003025-01
Funding for this conference was made possible (in part) by 1R13TR003025-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. This award reflects support from the NIH Common Fund Somatic Cell Genome Editing (SCGE) program in the amount of $22,200 total costs.